ReNeuron Group plc Directors Share Purchases (2127C)

TIDMRENE

RNS Number : 2127C

ReNeuron Group plc

27 September 2018

 
 27 September 2018   AIM: RENE 
 

ReNeuron Group plc

("ReNeuron" or the "Company")

Directors Share Purchases

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, was informed on 27 September 2018 that, on the same day, the following purchases of the Company's ordinary shares of 1p each ("Ordinary Shares") were made by directors of the Company:

 
 Name                 Title              Number         Total beneficial   Percentage 
                                          of Ordinary    interest in        of Company's 
                                          Shares         the Company's      Total Voting 
                                          purchased      Ordinary Shares    Rights 
                      Chief Executive 
 Olav Hellebø     Officer           14,936         21,630             0.068 
                     -----------------  -------------  -----------------  -------------- 
                      Chief Financial 
 Michael Hunt          Officer           7,462          27,546             0.087 
                     -----------------  -------------  -----------------  -------------- 
 

ENQUIRIES:

 
ReNeuron                                                            [phone] 
Olav Hellebø, Chief Executive Officer 
Michael Hunt, Chief Financial Officer 
Buchanan                                                            [phone] 
Mark Court, Sophie Cowles, Tilly Abraham 
 
Stifel Nicolaus Europe Limited                                      [phone] 
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Broker) 
 

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise be unable to reach their site of action.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further detail:

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

(Disclosure in relation to purchase of Ordinary Shares)

 
       Details of the person discharging managerial responsibilities 
   1    / person closely associated 
 a)    Name                         Olav Hellebo 
      ---------------------------  ----------------------------------- 
 2     Reason for the notification 
      ---------------------------------------------------------------- 
 a)    Position/status              Chief Executive Officer 
      ---------------------------  ----------------------------------- 
 b)    Initial notification         Initial notification 
        /Amendment 
      ---------------------------  ----------------------------------- 
 3     Details of the issuer, emission allowance market 
        participant, auction platform, auctioneer or auction 
        monitor 
      ---------------------------------------------------------------- 
 a)    Name                         ReNeuron Group plc 
      ---------------------------  ----------------------------------- 
 b)    LEI                          N/A 
      ---------------------------  ----------------------------------- 
 4     Details of the transaction(s): section to be repeated 
        for (i) each type of instrument; (ii) each type of 
        transaction; (iii) each date; and (iv) each place 
        where transactions have been conducted 
      ---------------------------------------------------------------- 
 a)    Description of the           Ordinary Shares 0.01p 
        financial instrument, 
        type of instrument           RENE - GB00B0DZML60 
        Identification code 
      ---------------------------  ----------------------------------- 
 b)    Nature of the transaction    Purchase of ordinary shares 
      ---------------------------  ----------------------------------- 
 c)    Price(s) and volume(s)         Price(s)   Volume(s) 
                                       66.9p      14,936 
                                                 ---------- 
      ---------------------------  ----------------------------------- 
 d)    Aggregated information       N/A 
      ---------------------------  ----------------------------------- 
 e)    Date of the transaction      27 September 2018 
      ---------------------------  ----------------------------------- 
 f)    Place of the transaction     London Stock Exchange, AIM Market 
      ---------------------------  ----------------------------------- 
 
 
       Details of the person discharging managerial responsibilities 
   1    / person closely associated 
 a)    Name                         Michael Hunt 
      ---------------------------  ----------------------------------- 
 2     Reason for the notification 
      ---------------------------------------------------------------- 
 a)    Position/status              Chief Financial Officer 
      ---------------------------  ----------------------------------- 
 b)    Initial notification         Initial notification 
        /Amendment 
      ---------------------------  ----------------------------------- 
 3     Details of the issuer, emission allowance market 
        participant, auction platform, auctioneer or auction 
        monitor 
      ---------------------------------------------------------------- 
 a)    Name                         ReNeuron Group plc 
      ---------------------------  ----------------------------------- 
 b)    LEI                          N/A 
      ---------------------------  ----------------------------------- 
 4     Details of the transaction(s): section to be repeated 
        for (i) each type of instrument; (ii) each type of 
        transaction; (iii) each date; and (iv) each place 
        where transactions have been conducted 
      ---------------------------------------------------------------- 
 a)    Description of the           Ordinary Shares 0.01p 
        financial instrument, 
        type of instrument           RENE - GB00B0DZML60 
        Identification code 
      ---------------------------  ----------------------------------- 
 b)    Nature of the transaction    Purchase of ordinary shares 
      ---------------------------  ----------------------------------- 
 c)    Price(s) and volume(s)         Price(s)   Volume(s) 
                                       67p        7,462 
                                                 ---------- 
      ---------------------------  ----------------------------------- 
 d)    Aggregated information       N/A 
      ---------------------------  ----------------------------------- 
 e)    Date of the transaction      27 September 2018 
      ---------------------------  ----------------------------------- 
 f)    Place of the transaction     London Stock Exchange, AIM Market 
      ---------------------------  ----------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHLLFEVATIDFIT

(END) Dow Jones Newswires

September 27, 2018 10:02 ET (14:02 GMT)